Theravance Biopharma (NASDAQ: TBPH) reported Q1 EPS of ($0.24), $0.01 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $14.5 million versus the consensus estimate of $14.92 million.

2024 Financial Guidance

Operating Expenses (excluding share-based compensation): The Company continues to expect full year 2024 R&D expenses of $30 million to $36 million and SG&A expenses of $45 million to $55 million, in each case excluding share-based compensation.

Share-Based Compensation: The Company continues to expect full year share-based compensation expenses of $18 million to $22 million.

Non-GAAP Net Profit / Loss: The Company continues to expect Non-GAAP net loss in the first half of 2024 and to approach non-GAAP breakeven in the second half of 2024; limited cash burn expected in 2024.

For earnings history and earnings-related data on Theravance Biopharma (TBPH) click here.